medigraphic.com
ISSN 1560-4381 (Print)

2020, Number 4

<< Back Next >>

Correo Científico Médico 2020; 24 (4)

Advances in the treatment of rheumatoid arthritis to control cardiovascular risk

Valencia ALA, Prado PNA, Álvarez VAJ, Sambache HEF, Panamá HEE

Language: Spanish
References: 42
Page: 1263-1287
PDF size: 300.85 Kb.


ABSTRACT

Rheumatoid arthritis is a systemic autoimmune disease with a high risk of cardiac morbidity and mortality. This literature review describes the complex, not well understood, physiopathology that links both diseases and the main advances in treatment options. For this purpose, with the descriptor "rheumatoid arthritis", the following databases were searched: PubMed Central of the US National Library of Medicine, National Institutes of Health (https://www.ncbi.nlm.nih.gov/pmc), Scientific Electronic Library Online (SciELO) (https://search.scielo.org) and ClinicalKey (https://www.elsevier.com). The articles selected were, mainly, from the last 5 years.


REFERENCES

  1. England B, Thiele G, Anderson D, Mikuls T. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018[citado 10/02/2019];361: 1036. Disponible en: https://www.bmj.com/content/361/bmj.k1036.abstract

  2. Mestanza Mera CA. Polimorfismos en la región promotora del gen de Necrosis Tumoral alfa (TNF-α) en pacientes ecuatorianos diagnosticados con Artritis Reumatoide.[Tesis][Quito]: Universidad Central de Ecuador;2012. 58p. Disponible en: http://www.dspace.uce.edu.ec/bitstream/25000/695/3/T.UCE-0008-01.pdf

  3. González ML, Rueda J, González H, Cantor E, Martínez A. Artritis reumatoide temprana: resultados clínicos y funcionales de una cohorte en un centro de alta complejidad, Cali-Colombia. Rev Colomb Reumatol. 2016[citado 08/05/2019];23(3):148–154.Disponible en: http://www.scielo.org.co/pdf/rcre/v23n3/v23n3a02.pdf

  4. Alpizar Campo R, Díaz Coto JF, Vega Ortiz JM, Momge Zeledón P, Arrieta Vega D, Sáenz Castro R. Guías de manejo de artritis reumatoide. Consenso 2016. Asociación Costarricense de Reumatología. Acta Méd Costarric. 2017[citado 10/05/2019];59(3):103-109.Disponible en: https://www.scielo.sa.cr/scielo.php?pid=s0001-60022017000300103&script=sci_arttext

  5. Nair B, Taylor-Gjevre R, Wu L, Jin S, Quail JM. Incidence and prevalence of rheumatoid arthritis in Saskatchewan, Canada: 2001–2014. BMC Rheumatology. 2019[citado 10/04/2020]; 3:28. Disponible en: https://bmcrheumatol.biomedcentral.com/articles/10.1186/s41927-019-0077-4

  6. Urman A , Taklalsingh N, Sorrento C, McFarlane IM. Inflammation beyond the Joints: Rheumatoid Arthritis and Cardiovascular Disease. Scifed J Cardiol. 2018[citado 10/05/2020]; 2(3):1000019. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312687/pdf/nihms-1002721.pdf

  7. Jagpal A, Navarro Millán I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatology. 2018[citado 10/02/2020]; 2:10. Disponible en: https://doi.org/10.1186/s41927-018-0014-y

  8. Masoud S, Lim Boon P, Kitas GD, Panoulas V. Sudden cardiac death in patients with rheumatoid arthritis. World J Cardiol. 2017[citado 10/02/2020]; 9(7):562-573. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545140/

  9. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res.2018[citado 10/04/2020];6:15. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920070/

  10. Van Onna M, Boonen A. The challenging interplay between rheumatoid arthritis, ageing and comorbidities. BMC Musculoskeletal Disorders. 2016[citado 29/05/2020]; 17:184. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845363/pdf/12891_2016_Article_1038.pdf

  11. Wang L, Zhang Y, Zhang SY. Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future. Chin Med J.2019[citado 10/04/2020];132(24): 2972-2983. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964948/pdf/cm9-132-2972.pdf

  12. Løppenthin K, Esbensen BA, Østergaard M, Ibsen R, Kjellberg J, Jennum P. Morbidity and mortality in patients with rheumatoid arthritis compared with an age- and sex-matched control population: A nationwide register study. J Comorb. 2019[citado 28/05/2020]; 9: 1–7. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547169/pdf/10.1177_2235042X19853484.pdf

  13. Terao C, Raychaudhuri S, Gregersen PK. Recent Advances in Defining the Genetic Basis of Rheumatoid Arthritis. Annu Rev Genomics Hum Genet. 2016[citado 10/08/2020]; 17: 273–301. Disponible en: https://www.annualreviews.org/doi/abs/10.1146/annurev-genom-090314-045919?journalCode=genom

  14. Viatte S, Barton A. Genetics of rheumatoid arthritis susceptibility, severity, and treatment response. Semin Immunopathol. 2017[citado15/05/2020];39(4):395–408. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486781/pdf/281_2017_Article_630.pdf

  15. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017[citado 10/04/2020]; 31(1): 3–18. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726551/pdf/nihms906783.pdf

  16. Ishikawa Y, Terao C. The Impact of Cigarette Smoking on Risk of Rheumatoid Arthritis: A Narrative Review. Cells. 2020[citado 10/02/2020]; 9(2):475. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072747/pdf/cells-09-00475.pdf

  17. Nemtsova MV, Zaletaev DV, Bure IV, Mikhaylenko DS, Kuznetsova EB, Alekseeva EA, et al. Epigenetic Changes in the Pathogenesis of Rheumatoid Arthritis. Front Genet. 2019[citado 25/05/ 2019];10:570. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587113/pdf/fgene-10-00570.pdf

  18. Bermúdez Garcell A, Serrano Gámez NB, Teruel Ginés R, Sánchez Sánchez R, Sigcho Romero CR. Mecanismos básicos de la epigenética. CCM.2020 [citado15/05/2020];24(1).Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/3448

  19. Chico Capote A, Uguña Sari F, Estévez del Toro M, Rodríguez López M, Hidalgo Costa T. Riesgo cardiovascular en pacientes con artritis reumatoide. Acta Médica. 2019[citado 30/09/2019]; 20 (2): 1561-3186. Disponible en: http://www.revactamedica.sld.cu/index.php/act/article/view/24/14

  20. Montiel de Jarolín DE, Holtzberger S, Gill C. Frecuencia de dislipidemia y otros factores de riesgo cardiovascular en pacientes con artritis reumatoide. Rev Nac(Itauguá).2018[citado 15/02/2019];10(2): 93-104. Disponible: http://scielo.iics.una.py/scielo.php?script=sci_arttext&pid=S2072-81742018000200093&lng=en&nrm=iso&tlng=es

  21. Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskel Dis. 2016[citado36/05/2019];8(3):86–101. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872174/pdf/10.1177_1759720X16643340.pdf

  22. Hallajzadeh J, Safiri S, Mansournia MA, Khoramdad M, Izadi N, Almasi-Hashiani A, et al. Metabolic syndrome and its components among rheumatoid arthritis patients: A comprehensive updated systematic review and meta-analysis. PLoS ONE. 2017[citado 09/09/2010];12(3):0170361. Disponible en: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170361

  23. Jeong H, Young Baek S, Woo Kim S, Hee Eun Y, Young Kim I, Kim H, et al. Correction: Comorbidities of rheumatoid arthritis: Results from the Korean National Health and Nutrition Examination Survey. PLoS ONE. 2017[citado 15/06/2019];12(5):0176260. Disponible en: https://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0178309

  24. Ramírez Huaranga MA, Minguez Sánchez MD, Zarca Díaz de la Espina MA, Ramos Rodríguez M, Cuadra-Díaz JL, Romero Aguilera G. Artritis reumatoide, una enfermedad sistémica con un riesgo cardiovascular subestimado. Rev Colomb Reumatol. 2018[citado 20/02/2019];25(2):92-98. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232018000200092&lng=en

  25. de Armas Hernández A, Solís Cartas U, Prada Hernández DM,Benítez Falero Y, Vázquez Abreu RL, et al. Factores de riesgo ateroscleróticos en pacientes con artritis reumatoide. Rev Cub Med Mil. 2017[citado 25/05/2019];46(1):51-63. Disponible en: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/5/40

  26. Hernández Muñiz Y, López Mantecón AM, Pozo Abreu SM, Torres Carballeira R, Carrillo Reyes C, Martínez Sánchez A, et al. Factores de riesgo para la aparición de aterosclerosis en pacientes con artritis reumatoide. Rev Cubana Reumatol. 2019[citado09/05/2020];21(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1817-59962019000300006

  27. Mousaad Elemam N, Hannawi S, Maghazachi AA. Role of Chemokines and Chemokine Receptors in Rheumatoid Arthritis. Immunoargets Ther. 2020[citado 25/08/2020]; 9:43-56. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7074856/pdf/itt-9-43.pdf

  28. Feria Díaz GE, Leyva Proenza CA, Concepción Parra W, Castro Maquilón AG, Larrea Meza IS. Papel de las citoquinas en la fisiopatología de la artritis reumatoide.CCM.2020 [citado 08/06/2020];24(1).Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/3447

  29. Carrión M, Frommer KW, Pérez García S, Müller Ladner U, Gomariz RP, Neumann E. The Adipokine Network in Rheumatic Joint Diseases. Int J Mol Sci. 2019[citado 26/06/2020];20(17): 4091. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747092/pdf/ijms-20-04091.pdf

  30. Fang Q, Ou J,Selva Nandakumar K. Autoantibodies as Diagnostic Markers and Mediator of Joint Inflammation in Arthritis. Mediators Inflamm.2019[citado 03/04/2020];2019: 6363086. Disponible en: https://doi.org/10.1155/2019/6363086

  31. Volkov M, van Schie KA, van der Woude D. Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology. Immunol Rev. 2020[citado 14/9/2020]; 294(1):148–163. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1111/imr.12829

  32. Carubbi F, Alunno A, Gerli R, Giacomelli R. Post-Translational Modifications of Proteins: Novel Insights in the Autoimmune Response in Rheumatoid Arthritis. Cells. 2019[citado 25/11/2019]; 8(7):657.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678491/pdf/cells-08-00657.pdf

  33. Lucchino B,Romani Spinelli F, Iannuccelli C, Guzzo MP, Conti F, Di Franco M. Mucosa–Environment Interactions in the Pathogenesis of Rheumatoid Arthritis. Cells. 2019[citado 30/11/019];8(7):700. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678242/pdf/cells-08-00700.pdf

  34. DeMizio DJ, Geraldino-Pardilla LB. Autoimmunity and Inflammation Link to Cardiovascular Disease Risk in Rheumatoid Arthritis. Rheumatol Ther. 2020; 7:19–33.

  35. Khanna S, Jaiswal Sagar K ,Gupta B. Managing Rheumatoid Arthritis with Dietary Interventions. Front Nutr. 2017[citado 25/08/2019];4:52.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682732/pdf/fnut-04-00052.pdf

  36. Mulhearn B, Barton A, Viatte S. Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis. J Pers Med. 2019[citado 28/09/2020];9(4):46.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963853/pdf/jpm-09-00046.pdf

  37. Camacho Castillo KP, Martínez Verdezoto TP, Urbina Aucancela KD, Urbina Aucancela CY, Callay Vimos JJ. Actualidades médicas en Reumatología y su aplicación en América Latina: tratamiento de artritis reumáticas inflamatorias. CCM.2020 [citado 25/05/2020];24(1).Disponible en: http://www.revcocmed.sld.cu/index.php/cocmed/article/view/3386

  38. Humphreys J, Hyrich K, Symmons D. What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? Arthritis Res Ther.2016[citado 06/05/2019]; 18(1):282. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134078/pdf/13075_2016_Article_1176.pdf

  39. Błyszczuk P, Szekanecz Z. Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis. RMD Open. 2020[citado 28/07/2020];6(1):001032. Disponible en: 10.1136/rmdopen-2019-001032. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046979/pdf/rmdopen-2019-001032.pdf

  40. Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM, et al. A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019[citado 06/05/2020];71(9): 1437–1449. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771601/pdf/ART-71-1437.pdf

  41. Singh JA, Hossain A, Tanjong Ghogomu E, Mudano AS, Maxwell LJ, Buchbinder R, et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017[citado 15/05/2019];3(3). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6472522/pdf/CD012591.pdf

  42. Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs in Context.2019[citado 25/11/0219]; 8: 212595. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821397/pdf/dic-8-212595.pdf




2020     |     www.medigraphic.com